Medtronic (MDT) reported $8.58 billion in revenue for the quarter ended July 2025, representing a year-over-year increase of 8.4%. EPS of $1.26 for the same period compares to $1.23 a year ago.
The reported revenue represents a surprise of +2.5% over the Zacks Consensus Estimate of $8.37 billion. With the consensus EPS estimate being $1.23, the EPS surprise was +2.44%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Medtronic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- U.S. Revenue: $4.22 billion versus the three-analyst average estimate of $4.27 billion. The reported number represents a year-over-year change of +3.5%.
- Net Sales- U.S. Revenue- Neuroscience- Specialty Therapies: $393 million versus the two-analyst average estimate of $411.13 million. The reported number represents a year-over-year change of -1.3%.
- Net Sales- ROW- Neuroscience: $792 million versus the two-analyst average estimate of $786.29 million. The reported number represents a year-over-year change of +5.3%.
- Net Sales- U.S. Revenue- Neuroscience- Cranial & Spinal Technologies: $890 million versus $903.74 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.1% change.
- Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies: $702 million versus the five-analyst average estimate of $729.77 million. The reported number represents a year-over-year change of -1.5%.
- Net Sales- World Wide Revenue- Cardiovascular- Coronary & Peripheral Vascular: $643 million compared to the $633.03 million average estimate based on five analysts. The reported number represents a change of +4.4% year over year.
- Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies: $1.21 billion compared to the $1.21 billion average estimate based on five analysts. The reported number represents a change of +5.6% year over year.
- Net Sales- World Wide Revenue- Neuroscience- Neuromodulation: $504 million versus $493.22 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +10.3% change.
- Net Sales- World Wide Revenue- Diabetes: $721 million compared to the $706.66 million average estimate based on five analysts. The reported number represents a change of +11.4% year over year.
- Net Sales- World Wide Revenue- Cardiovascular- Cardiac Rhythm & Heart Failure: $1.71 billion compared to the $1.66 billion average estimate based on five analysts. The reported number represents a change of +11.5% year over year.
- Net Sales- World Wide Revenue- Medical Surgical: $2.08 billion versus the five-analyst average estimate of $2.06 billion. The reported number represents a year-over-year change of +4.4%.
- Net Sales- World Wide Revenue- Cardiovascular: $3.29 billion compared to the $3.2 billion average estimate based on five analysts. The reported number represents a change of +9.3% year over year.
View all Key Company Metrics for Medtronic here>>>
Shares of Medtronic have returned +3.5% over the past month versus the Zacks S&P 500 composite's +2.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Medtronic PLC (MDT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
